Robert Whitfield MDAmerica's Breast Implant Illness Expert™

Sharps Methods: Unlocking Patient Recovery Secrets Revealed #shorts

11 Jun 2026 · 1 min

Watch on YouTube

1:17

In this interview, Dr. Robert Whitfield MD explains the origins of the Sharps Methods, a protocol developed to improve outcomes for patients undergoing explant surgery. He describes three distinct recovery trajectories observed among his patients: roughly one‑third recover quickly after surgery, another third take six to twelve months to improve, and the remaining third show little to no improvement despite surgery. To address the challenging non‑responders, Dr. Whitfield began investigating underlying biological factors, focusing on methylation issues and specific genetic markers such as FUT2, COMT, and MTHFR, initially using 23andMe and later full genome sequencing as costs decreased. He also incorporated comprehensive toxicity testing to further tailor treatment, forming the basis of the Sharps Methods approach.

Chapters

When you created the Sharps Methods, tell me a little bit about how did that come about and what is it that made you recognize that what most surgeons were doing, especially when it comes to explant, may not be enough?
Yeah, it was fascinating. So we took care of these patients and more and more of the patients kept coming and we'll say a third of them got well relatively quickly after surgery. So those are the patients you would assume who had infections or ruptures or capture contractures with leakage or whatever the series of problems were. But then, you know, a third would take, you know, we'll say 6 to 12 months to get better. And then you had a third that really didn't get better, Dr. Fab, and that was a very, very difficult group to manage because they went through the surgery, they want to get better. So then we started digging deeper and we already understood there were methylation issues. And, you know, we had early things like 23andMe and we'd look at FUT2 and COMT and MTHFR. And now you can basically get the entire genome done, you know, for a relatively inexpensive amount. And then we used more and more toxicity testing.